Literature DB >> 32753690

Complex landscape of alternative splicing in myeloid neoplasms.

Torsten Haferlach1, Jaroslaw P Maciejewski2, Richard A Padgett3, Courtney E Hershberger4, Devlin C Moyer4, Vera Adema2, Cassandra M Kerr2, Wencke Walter1, Stephan Hutter1, Manja Meggendorfer1, Constance Baer1, Wolfgang Kern1, Niroshan Nadarajah1, Sven Twardziok1, Mikkael A Sekeres2, Claudia Haferlach1.   

Abstract

Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with little overlap. However, previous studies lacked the power necessary to identify commonly mis-spliced transcripts in heterogeneous patient cohorts. By performing RNA-Seq on bone marrow samples from 1258 myeloid neoplasm patients and 63 healthy bone marrow donors, we identified transcripts frequently mis-spliced by mutated splicing factors (SF), rare SF mutations with common alternative splicing (AS) signatures, and SF-dependent neojunctions. We characterized 17,300 dysregulated AS events using a pipeline designed to predict the impact of mis-splicing on protein function. Meta-splicing analysis revealed a pattern of reduced levels of retained introns among disease samples that was exacerbated in patients with splicing factor mutations. These introns share characteristics with "detained introns," a class of introns that have been shown to promote differentiation by detaining pro-proliferative transcripts in the nucleus. In this study, we have functionally characterized 17,300 targets of mis-splicing by the SF mutations, identifying a common pathway by which AS may promote maintenance of a proliferative state.

Entities:  

Year:  2020        PMID: 32753690     DOI: 10.1038/s41375-020-1002-y

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  57 in total

1.  Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis.

Authors:  C Wang; K Chua; W Seghezzi; E Lees; O Gozani; R Reed
Journal:  Genes Dev       Date:  1998-05-15       Impact factor: 11.361

2.  Functional recognition of the 3' splice site AG by the splicing factor U2AF35.

Authors:  S Wu; C M Romfo; T W Nilsen; M R Green
Journal:  Nature       Date:  1999-12-16       Impact factor: 49.962

3.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

4.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.

Authors:  Hideki Makishima; Valeria Visconte; Hirotoshi Sakaguchi; Anna M Jankowska; Sarah Abu Kar; Andres Jerez; Bartlomiej Przychodzen; Manoj Bupathi; Kathryn Guinta; Manuel G Afable; Mikkael A Sekeres; Richard A Padgett; Ramon V Tiu; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-02-09       Impact factor: 22.113

5.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.

Authors:  Chantana Polprasert; Isabell Schulze; Mikkael A Sekeres; Hideki Makishima; Bartlomiej Przychodzen; Naoko Hosono; Jarnail Singh; Richard A Padgett; Xiaorong Gu; James G Phillips; Michael Clemente; Yvonne Parker; Daniel Lindner; Brittney Dienes; Eckhard Jankowsky; Yogen Saunthararajah; Yang Du; Kevin Oakley; Nhu Nguyen; Sudipto Mukherjee; Caroline Pabst; Lucy A Godley; Jane E Churpek; Daniel A Pollyea; Utz Krug; Wolfgang E Berdel; Hans-Ulrich Klein; Martin Dugas; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Kenichi Yoshida; Seishi Ogawa; Carsten Müller-Tidow; Jaroslaw P Maciejewski
Journal:  Cancer Cell       Date:  2015-04-23       Impact factor: 31.743

6.  Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.

Authors:  Vikas Madan; Deepika Kanojia; Jia Li; Ryoko Okamoto; Aiko Sato-Otsubo; Alexander Kohlmann; Masashi Sanada; Vera Grossmann; Janani Sundaresan; Yuichi Shiraishi; Satoru Miyano; Felicitas Thol; Arnold Ganser; Henry Yang; Torsten Haferlach; Seishi Ogawa; H Phillip Koeffler
Journal:  Nat Commun       Date:  2015-01-14       Impact factor: 14.919

7.  PRPF8 defects cause missplicing in myeloid malignancies.

Authors:  A Kurtovic-Kozaric; B Przychodzen; J Singh; M M Konarska; M J Clemente; Z K Otrock; M Nakashima; E D Hsi; K Yoshida; Y Shiraishi; K Chiba; H Tanaka; S Miyano; S Ogawa; J Boultwood; H Makishima; J P Maciejewski; R A Padgett
Journal:  Leukemia       Date:  2014-04-30       Impact factor: 11.528

8.  Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

Authors:  Akihide Yoshimi; Kuan-Ting Lin; Daniel H Wiseman; Mohammad Alinoor Rahman; Alessandro Pastore; Bo Wang; Stanley Chun-Wei Lee; Jean-Baptiste Micol; Xiao Jing Zhang; Stephane de Botton; Virginie Penard-Lacronique; Eytan M Stein; Hana Cho; Rachel E Miles; Daichi Inoue; Todd R Albrecht; Tim C P Somervaille; Kiran Batta; Fabio Amaral; Fabrizio Simeoni; Deepti P Wilks; Catherine Cargo; Andrew M Intlekofer; Ross L Levine; Heidi Dvinge; Robert K Bradley; Eric J Wagner; Adrian R Krainer; Omar Abdel-Wahab
Journal:  Nature       Date:  2019-10-02       Impact factor: 69.504

9.  Spliceosome database: a tool for tracking components of the spliceosome.

Authors:  Ivan Cvitkovic; Melissa S Jurica
Journal:  Nucleic Acids Res       Date:  2012-10-30       Impact factor: 16.971

10.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

View more
  15 in total

Review 1.  Spliceosomal factor mutations and mis-splicing in MDS.

Authors:  Courtney E Hershberger; Noah J Daniels; Richard A Padgett
Journal:  Best Pract Res Clin Haematol       Date:  2020-08-01       Impact factor: 3.020

2.  Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms.

Authors:  Borwyn A Wang; Hrishikesh M Mehta; Srinivasa R Penumutchu; Blanton S Tolbert; Chonghui Cheng; Marek Kimmel; Torsten Haferlach; Jaroslaw P Maciejewski; Seth J Corey
Journal:  Leukemia       Date:  2022-08-08       Impact factor: 12.883

3.  Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status.

Authors:  Kristian Unger; Daniel F Fleischmann; Viktoria Ruf; Jörg Felsberg; Daniel Piehlmaier; Daniel Samaga; Julia Hess; Marian Preetham Suresh; Michel Mittelbronn; Kirsten Lauber; Wilfried Budach; Michael Sabel; Claus Rödel; Guido Reifenberger; Jochen Herms; Jörg-Christian Tonn; Horst Zitzelsberger; Claus Belka; Maximilian Niyazi
Journal:  Neurooncol Adv       Date:  2020-10-15

4.  Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

Authors:  Curtis A Lachowiez; Sanam Loghavi; Ken Furudate; Guillermo Montalban-Bravo; Abhishek Maiti; Tapan Kadia; Naval Daver; Gautam Borthakur; Naveen Pemmaraju; Koji Sasaki; Yesid Alvarado; Musa Yilmaz; Nicholas J Short; Kelly Chien; Maro Ohanian; Sherry Pierce; Keyur P Patel; Elias Jabbour; Farhad Ravandi; Hagop M Kantarjian; Guillermo Garcia-Manero; Koichi Takahashi; Marina Y Konopleva; Courtney D DiNardo
Journal:  Blood Adv       Date:  2021-04-27

5.  Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms.

Authors:  Noah J Daniels; Courtney E Hershberger; Xiaorong Gu; Caroline Schueger; William M DiPasquale; Jonathan Brick; Yogen Saunthararajah; Jaroslaw P Maciejewski; Richard A Padgett
Journal:  Cell Rep       Date:  2021-04-13       Impact factor: 9.423

6.  TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.

Authors:  Carmelo Gurnari; Simona Pagliuca; Yihong Guan; Vera Adema; Courtney E Hershberger; Ying Ni; Hassan Awada; Sunisa Kongkiatkamon; Misam Zawit; Diego F Coutinho; Ilana R Zalcberg; Jae-Sook Ahn; Hyeoung-Joon Kim; Dennis Dong Hwan Kim; Mark D Minden; Joop H Jansen; Manja Meggendorfer; Claudia Haferlach; Babal K Jha; Torsten Haferlach; Jaroslaw P Maciejewski; Valeria Visconte
Journal:  Blood Adv       Date:  2022-01-11

7.  Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment.

Authors:  Congbo Yue; Tianyi Zhao; Shoucai Zhang; Yingjie Liu; Guixi Zheng; Yi Zhang
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

Review 8.  Alternative Splicing in Myeloid Malignancies.

Authors:  Carmelo Gurnari; Simona Pagliuca; Valeria Visconte
Journal:  Biomedicines       Date:  2021-12-06

Review 9.  MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.

Authors:  Rahaba Marima; Flavia Zita Francies; Rodney Hull; Thulo Molefi; Meryl Oyomno; Richard Khanyile; Sikhumbuzo Mbatha; Mzubanzi Mabongo; David Owen Bates; Zodwa Dlamini
Journal:  Biomedicines       Date:  2021-12-02

10.  A Deep Exon Cryptic Splice Site Promotes Aberrant Intron Retention in a Von Willebrand Disease Patient.

Authors:  John G Conboy
Journal:  Int J Mol Sci       Date:  2021-12-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.